Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 15,500 | |||
5 mg | 在庫あり | ¥ 37,500 | |||
10 mg | 在庫あり | ¥ 62,500 | |||
25 mg | 在庫あり | ¥ 112,500 | |||
50 mg | 在庫あり | ¥ 169,500 | |||
100 mg | 在庫あり | ¥ 226,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 41,000 |
説明 | BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases. |
ターゲット&IC50 | BTK:0.3 nM (Kd), BTK:1 nM (IC50) |
In vitro | BIIB068 inhibits B cell, neutrophil and monocyte activation in vitro, but not T cell responses. |
In vivo | BIIB068 demonstrated good PK/PD correlation with in vivo EC50 = 0.16 μM based on antibody esponse, similar to in vivo WB pBTK potency in mice. BIIB068 exhibited no adverse effects in the single dose CNS and respiratory studies in rats nor in a single dose cardiovascular study in monkeys. BIIB068 was well tolerated and effective at inhibiting BTK phosphorylation in healthy subjects. |
分子量 | 435.52 |
分子式 | C23H29N7O2 |
CAS No. | 1798787-27-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL(68.88 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BIIB068 1798787-27-5 Angiogenesis Tyrosine Kinase/Adaptors BTK ADME inhibit FcγR Autoimmune Bruton tyrosine kinase TNFα BIIB 068 BIIB-068 ROS Inhibitor reversible Btk anti-IgD phosphorylation anti-IgM inhibitor